Data validate MyoKardia’s mavacamten in subset of cardiomyopathy, suggest broader applications

Positive data for MyoKardia’s mavacamten in obstructive hypertrophic cardiomyopathy sent the company’s shares up nearly 60% on Monday and signaled to investors that the cardiac myosin inhibitor may have success that translates beyond this subset of patients.

MyoKardia Inc. (NASDAQ:MYOK) announced mavacamten met all of the primary and secondary endpoints with p values below 0.0006 in top-line results from the Phase III EXPLORER-HCM trial. It also had a comparable safety profile to placebo, quelling fears over dose-related drops in left ventricular ejection fraction (LVEF) below the normal range...